Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

F. J. Giles, E. Abruzzese, G. Rosti, D. W. Kim, R. Bhatia, A. Bosly, S. Goldberg, G. L.S. Kam, M. Jagasia, W. Mendrek, T. Fischer, T. Facon, U. Dünzinger, D. Marin, M. C. Mueller, Y. Shou, N. J. Gallagher, R. A. Larson, F. X. Mahon, M. BaccaraniJ. Cortes, H. M. Kantarjian

Research output: Contribution to journalArticlepeer-review

74 Scopus citations

Fingerprint

Dive into the research topics of 'Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences